These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29874001)

  • 21. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Physiatrists, and Psychiatrists.
    Choi JH; Kim JM; Yang HK; Lee HJ; Shin CM; Jeong SJ; Kim WS; Han JW; Yoon IY; Song YS; Bae YJ
    J Korean Med Sci; 2020 Jul; 35(28):e230. PubMed ID: 32686370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Parkinson's disease and sleep.
    Poewe W; Högl B
    Curr Opin Neurol; 2000 Aug; 13(4):423-6. PubMed ID: 10970059
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of Melissa officinalis supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina.
    Haybar H; Javid AZ; Haghighizadeh MH; Valizadeh E; Mohaghegh SM; Mohammadzadeh A
    Clin Nutr ESPEN; 2018 Aug; 26():47-52. PubMed ID: 29908682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of rotigotine on Parkinson's disease-related sleep disturbances.
    Antonini A; Calandrella D; Merello M; Koutsikos K; Pilleri M
    Expert Opin Pharmacother; 2013 Dec; 14(18):2571-80. PubMed ID: 24138154
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daytime sleepiness improvement following bilateral chronic electrical stimulation of the subthalamic nucleus in Parkinson's disease.
    Lopiano L; Rizzone M; Bergamasco B; Tavella A; Torre A; Melcarne A; Perozzo P; Lanotte M
    Eur Neurol; 2001; 46(1):49-50. PubMed ID: 11455184
    [No Abstract]   [Full Text] [Related]  

  • 27. Depression in Parkinson's disease.
    Rihmer Z; Gonda X; Döme P
    Ideggyogy Sz; 2014 Jul; 67(7-8):229-36. PubMed ID: 25509363
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Startling facts about emotion in Parkinson's disease: blunted reactivity to aversive stimuli.
    Bowers D; Miller K; Mikos A; Kirsch-Darrow L; Springer U; Fernandez H; Foote K; Okun M
    Brain; 2006 Dec; 129(Pt 12):3356-65. PubMed ID: 17095520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Non-dopaminergic treatments for Parkinson's disease].
    Derkinderen P
    Rev Neurol (Paris); 2010 Oct; 166(10):811-5. PubMed ID: 20832090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's Disease, Diabetes and Cognitive Impairment.
    Ashraghi MR; Pagano G; Polychronis S; Niccolini F; Politis M
    Recent Pat Endocr Metab Immune Drug Discov; 2016; 10(1):11-21. PubMed ID: 27396477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cognitive issues in Parkinson's disease.
    Elmer L
    Neurol Clin; 2004 Oct; 22(3 Suppl):S91-S106. PubMed ID: 15501368
    [No Abstract]   [Full Text] [Related]  

  • 32. [Drug treatment is beneficial also for elderly patients with Parkinson disease. Important to consider also other co-existing diseases].
    Granérus AK
    Lakartidningen; 2001 Mar; 98(13):1515-23. PubMed ID: 11330147
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs of abuse and Parkinson's disease.
    Mursaleen LR; Stamford JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():209-17. PubMed ID: 25816790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment of Parkinson disease: a review.
    Connolly BS; Lang AE
    JAMA; 2014 Apr 23-30; 311(16):1670-83. PubMed ID: 24756517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intervening in the neuropsychiatric features of Parkinson's disease.
    Weintraub D; Stern MB
    Expert Rev Neurother; 2007 Jun; 7(6):699-710. PubMed ID: 17563252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of the behavioral aspects of Parkinson's disease.
    Borek LL; Chou KL; Friedman JH
    Expert Rev Neurother; 2007 Jun; 7(6):711-25. PubMed ID: 17563253
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Sleep disturbances in Parkinson's disease: characteristics, evaluation and therapeutic approaches].
    Faludi B; Janszky J; Komoly S; Kovács N
    Orv Hetil; 2015 Jul; 156(27):1091-9. PubMed ID: 26122904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of early Parkinson's disease. Part 2.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):206-15. PubMed ID: 19176961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug treatment of non-motor symptoms in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2002 Apr; 3(4):381-8. PubMed ID: 11934340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopaminergic Therapies for Non-motor Symptoms in Parkinson's Disease.
    Schaeffer E; Berg D
    CNS Drugs; 2017 Jul; 31(7):551-570. PubMed ID: 28643183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.